Oculis Welcomes Daniel S. Char to Leadership Team
Oculis Holding AG, a pioneering global biopharmaceutical company dedicated to eye care, has announced an important addition to its leadership team. Daniel S. Char has been appointed as the new Chief Legal Officer. His extensive experience in legal management within the biotech and medical device sectors positions him well to support Oculis as it advances its innovative pipeline.
Bringing Valuable Expertise to Oculis
Mr. Char is not just any legal professional; he brings over 35 years of comprehensive experience in leading legal, compliance, and corporate governance functions. His background spans both large and burgeoning biotech firms, providing him with unique insights that are invaluable to Oculis.
A Critical Time for Oculis
The timing of Mr. Char's appointment is crucial as Oculis embarks on an exciting phase in its development. With several promising products advancing towards commercialization, the leadership and expertise of Mr. Char will be critical in steering the company's strategic objectives.
Comments from the Executive Team
Riad Sherif, the Chief Executive Officer of Oculis, expressed enthusiasm about Mr. Char's arrival. He stated, "We are delighted to welcome Daniel to Oculis. This appointment exemplifies our continued execution of Oculis' strategic plan to advance our innovative pipeline and bring differentiated products to patients, starting with OCS-01 as the first topical eye drop in retina."
Daniel S. Char's Reflections
Echoing the thrill of his appointment, Mr. Char stated, "I am thrilled to have the opportunity to join Oculis, a company known for its strategic excellence and continuously evolving milestones. I look forward to collaborating with a talented team as we pursue our vision of becoming a world leader in ophthalmology."
A Track Record of Success
Before joining Oculis, Mr. Char served as Chief Legal Officer and Corporate Secretary at ImmunoGen. His prior roles include General Counsel and Corporate Secretary for Evelo Biosciences and various senior legal positions at prominent biotech firms, including Smith & Nephew and Biogen. His journey began at Goodwin Procter, where he developed his foundational skills in corporate law.
About Oculis: A Commitment to Eye Care Innovation
Oculis is a global biopharmaceutical company purposefully driven to save sight and enhance eye care. Their diverse and highly differentiated pipeline includes several innovative product candidates. Among them is OCS-01, a topical eye drop candidate designed for diabetic macular edema and inflammation following cataract surgery. The pipeline also features OCS-02, aimed at dry eye disease and anterior uveitis, and OCS-05, which targets acute optic neuritis. Oculis operates out of Switzerland while also maintaining a presence in the U.S. and Iceland, with an overarching goal of improving quality of life for patients worldwide.
Oculis Contact Information
For additional information regarding Oculis and its initiatives, interested parties can reach out to Ms. Sylvia Cheung, CFO via email: sylvia.cheung@oculis.com.
Frequently Asked Questions
What role has Daniel S. Char been appointed to at Oculis?
Daniel S. Char has been appointed as the Chief Legal Officer of Oculis.
What experience does Daniel S. Char bring to Oculis?
Mr. Char brings over 35 years of legal experience from biotech and medical device companies.
What is Oculis focused on?
Oculis is focused on developing innovative treatments for eye care, aiming to improve patient outcomes.
What products are in Oculis' pipeline?
Oculis' pipeline includes OCS-01 for diabetic macular edema and other inflammation-related therapies.
How can someone contact Oculis?
For contact information, individuals can reach out to CFO Sylvia Cheung via email.
